Price (delayed)
$1.7
Market cap
$88.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.42
Enterprise value
$91.18M
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the
There are no recent dividends present for GTHX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.